Ranbaxy Laboratories surprised investors with a quarterly loss of 4.92 billion rupees ($90.95 million), thanks to the cost of recalling its generic version of Lipitor. Analysts had expected a profit of 1.44 billion rupees ($26.62 million). "This raises serious questions about transparency," IndiaNivesh analyst Daljeet Kohli told Reuters. Report